综合多组学分析确定了CDO1作为骨关节炎的新疗法标
Zhihu Zhao1,2, Xiangdong Wu3, Duan Wang4
1Clinical School of Orthopedics, Tianjin Medical University, Tianjin, 300000, China.
Endocrine, metabolic & immune disorders drug targets
|September 29, 2025
概括
这项研究使用多omics分析识别了CDO1作为一种新的骨关节炎 (OA) 风险基因. 在大鼠中抑制CDO1显著减缓了OA的进展,突出了其治疗潜力.
科学领域:
- 基因组学就是基因组学.
- 分子生物学分子生物学
- 生物医学研究生物医学研究
背景情况:
- 骨关节炎 (OA) 是一种具有复杂遗传基础的退行性关节疾病.
- 识别关键基因和治疗点对于开发有效的OA治疗非常重要.
研究的目的:
- 为了确定新型基因和潜在的治疗点骨关节炎 (OA) 进展.
- 通过使用综合的多omics方法来研究候选基因在OA发展中的因果关系.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 和大量RNA-seq数据的综合分析.
- 权重基因共同表达网络分析 (WGCNA) 用于识别共同表达的基因模块.
- 门德尔随机化 (MR) 分析以评估基因与OA风险之间的因果关系.
- 在大鼠OA模型中对顶级候选基因 (CDO1) 的功能验证.
主要成果:
- 通过scRNA-seq和大量RNA-seq识别了11种细胞类型和数千个差异表达基因 (DEGs).
- WGCNA强调了一个关键的OA相关基因模块.
- 综合分析确定了932个重叠的DEG,涉及铁和PI3K-Akt信号传导等途径.
- 通过MR分析,CDO1被确定为OA的显著因果风险基因.
结论:
- CDO1 是一种新的关节骨炎风险基因.
- 在体内,CDO1抑制表明对OA进展有保护作用.
- CDO1代表了一种有前途的治疗关节炎的标.
相关概念视频
Osteoclasts in Bone Remodeling
3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K

